Filing Analysis
AVITA Medical, Inc. entered into a Global Amendment with Stedical Scientific, Inc. to modify existing distribution and manufacturing agreements. The amendment provides AVITA with rights of first offer for international territories and adjusts revenue-sharing percentages for PermeaDerm products.
🚩 Red Flags
- Mandatory minimum revenue sharing payments of $1.0 million in 2026 with 20% annual growth requirements through 2030 create significant cash flow obligations/revenue hurdles.
- Potential for channel conflict as Stedical is permitted to pursue certain U.S. markets not currently served by AVITA.
📋 Key Facts
- Entered into 'Global Amendment' on August 5, 2026, with Stedical Scientific, Inc.
- AVITA paid a $500,000 fee to secure rights of first offer/refusal for expansion into EU, UK, and Australia.
- Revenue share for PermeaDerm (sheet form) increases to 67%, subject to margin-based escalators.
- Revenue share for PermeaDerm (glove form) increases to 80%, subject to margin-based escalators.
- AVITA must reach $1.0 million in revenue sharing payments in 2026, with a 20% annual growth minimum through 2030.
- Stedical may commercialize PermeaDerm in certain unserved U.S. markets at a 10% premium over AVITA's manufacturing costs.
- International sales by Stedical (primarily Asia) will be priced at $200 per carton plus a 10% manufacturing fee.
This is an amendment to a previous 8-K filing regarding the results of AVITA Medical's Annual Meeting of Stockholders held on June 3, 2026. The company is disclosing its decision to hold advisory votes on executive compensation on an annual basis.
📋 Key Facts
- The meeting was held on June 3, 2026.
- Stockholders voted on the frequency of future advisory votes regarding executive compensation (Proposal 13).
- The highest number of votes cast was for a '1 Year' voting cycle (9,545,151 votes).
- The Board of Directors determined that future advisory votes on named executive officer compensation will be held every year.
- The next required vote to determine the frequency will occur no later than the 2032 Annual Meeting.
AVITA Medical has issued a warrant certificate to Perceptive Credit Holdings V, LP following stockholder approval at the June 3, 2026 Annual Meeting. This warrant is tied to a previously established $60 million senior secured credit facility.
📋 Key Facts
- Warrant issued on June 5, 2026, to Perceptive Credit Holdings V, LP.
- Initial warrant allows purchase of up to 500,000 shares of common stock at an exercise price of $3.4019.
- An additional 150,000 shares will vest if the company draws the 'Additional Commitment Amount' of $10 million by March 31, 2027.
- The warrant is part of a larger $60 million senior secured credit facility (of which $50 million was already available).
- Warrant shares are being registered via a Form S-3 registration statement and prospectus supplement filed June 5, 2026.
AVITA Medical reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Stockholders approved the election of directors, the appointment of Grant Thornton LLP as auditor, and several compensation and equity issuance proposals.
📋 Key Facts
- All seven named directors were elected to the Board.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- The maximum aggregate annual cash fee pool for non-executive directors was increased from $750,000 to $900,000.
- Stockholders approved the issuance of warrants for up to 650,000 shares of Common Stock to Perceptive Credit Holdings V, LP, related to a credit agreement dated January 13, 2026.
- Approval was granted for the issuance of additional Equity Securities up to 10% of issued capital per ASX Listing Rule 7.1A.
AVITA Medical, Inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed on May 14, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the detailed results was furnished as Exhibit 99.1.
- The filing was signed by David O'Toole, Chief Financial Officer.
AVITA Medical has appointed Cary Vance as its permanent President and CEO, effective April 30, 2026, following his service as Interim CEO since October 2025. The company also restructured its board leadership, appointing Jan Stern Reed as Chair of the Board.
📋 Key Facts
- Cary Vance appointed permanent President and CEO effective April 30, 2026.
- Vance's compensation includes a base salary of $702,000 and an 80% target bonus.
- Equity grants totaling approximately $3.35 million ($2,529,000 in RSUs/options and $825,000 in RSUs) are subject to stockholder approval at the 2027 Annual Meeting.
- Jan Stern Reed appointed Chair of the Board, terminating the Lead Independent Director position.
- Vance has 30 years of healthcare leadership experience, including executive roles at GE HealthCare and Covidien.
AVITA Medical, Inc. filed an 8-K to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2025.
📋 Key Facts
- Report date: February 12, 2026
- Reporting period: Q4 and Full Year ended December 31, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial performance.
- Signed by David O’Toole, Chief Financial Officer.
AVITA Medical entered into a $60 million senior secured credit facility with Perceptive Credit Holdings V, LP to refinance existing debt. The deal includes the issuance of warrants for up to 500,000 shares (plus an additional 150,000 if certain revenue targets are met) and contains aggressive penalty terms and restrictive covenants.
🚩 Red Flags
- High-cost debt: The interest rate floor (7.50%) and potential for a 4% premium on default are significant.
- Aggressive penalty terms: A 5% exit fee if shareholder approval is not obtained by Sept 30, 2026.
- Restrictive covenants: Includes limitations on incurring debt, making acquisitions, paying dividends, or disposing of assets.
- Potential dilution: Issuance of warrants for up to 650,000 total shares (if additional commitment is triggered).
- Default risk: Failure to meet specific revenue maintenance tests or shareholder approval deadlines triggers default.
📋 Key Facts
- Entered into a $60 million senior secured credit facility on January 13, 2026.
- Initial drawdown of $50 million was made at closing; an additional $10 million is available subject to net revenue requirements by March 31, 2027.
- Interest rate: SOFR + 4.00%, with a floor of 7.50% per annum (default rate is SOFR/base + 4.00%).
- Issuance of warrants for up to 500,000 shares at the lower of 10-day VWAP prior to closing or issuance date.
- The company must obtain shareholder approval in Australia by September 30, 2026, or face a 5% exit fee on principal.
- Failure to obtain Warrant Shareholder Approval by November 30, 2026, constitutes an event of default.
- Requires maintaining at least $5 million in unrestricted cash at all times.
AVITA Medical, Inc. announced the appointment of Joe Woody to its Board of Directors, effective January 1, 2026. Mr. Woody is a seasoned healthcare executive with significant leadership experience at major medical technology firms.
📋 Key Facts
- Joe Woody appointed to the Board of Directors effective January 1, 2026.
- Term expires at the Company’s 2026 Annual Meeting of Stockholders.
- Annual cash compensation for board services is $92,500.
- Initial equity grant valued at approximately $210,000 (30% stock options, 70% RSUs).
- Mr. Woody previously served as CEO of Avanos Medical and Acelity Holdings.
AVITA Medical entered into a Sixth Amendment to its existing credit agreement with affiliates of OrbiMed Advisors, LLC. The amendment modifies revenue covenants and includes a critical waiver regarding potential 'going concern' disclosures in upcoming filings.
🚩 Red Flags
- Going concern language waiver: The lender's willingness to waive a 'no going concern' clause strongly suggests the company may be facing significant liquidity or solvency risks.
- Covenant modification: Adjusting revenue covenants often indicates the company was at risk of breaching existing terms.
- Additional debt: Increasing principal balance, even by a small amount ($500k), to secure waivers is typical for companies in distressed positions.
📋 Key Facts
- Sixth Amendment to the October 18, 2023 Credit Agreement signed on November 5, 2025.
- Trailing 12-month revenue covenant modified to $70.0 million for the quarter ending December 31, 2025.
- Lenders waived the requirement that the Q3 (Sept 30, 2025) Form 10-Q must not contain 'going concern' language.
- Company agreed to add $500,000 to the existing $40,000,000 principal balance as consideration for the amendment.
- Interest on the additional $500,000 is payable effective November 1, 2025.
AVITA Medical, Inc. announced the departure of CEO James Corbett and his removal from the Board of Directors, effective October 16, 2025. The company has appointed Chairman Cary Vance as Interim CEO to provide leadership during this transition.
🚩 Red Flags
- Sudden departure of the Chief Executive Officer.
- Leadership transition typically introduces short-term operational uncertainty.
📋 Key Facts
- CEO James Corbett departed his roles as CEO and Director on October 16, 2025.
- The departure was stated to be not due to any disagreement regarding operations, policies, or practices.
- Cary Vance (current Chairman) appointed as Interim CEO effective immediately.
- Jan Reed appointed as Lead Independent Director of the Board.
- Interim CEO Cary Vance will receive an annualized base salary of $702,000 and a guaranteed bonus for fiscal 2025 of $140,000.
AVITA Medical, Inc. entered into a placement agreement with MST Financial Services Pty Limited to issue 17,201,886 CHESS Depositary Interests (CDIs) to Australian institutional and professional investors. The transaction is expected to raise approximately US$15 million.
🚩 Red Flags
- Dilutive impact: The issuance of 17.2 million CDIs (where 5 CDIs = 1 share) represents a significant amount of equity relative to existing shares.
- Complexity: Use of CHESS Depositary Interests (CDIs) for an Australian-focused placement can complicate the capital structure for US investors.
📋 Key Facts
- Placement Agreement entered into on August 12, 2025, with MST Financial Services Pty Limited.
- Total CDIs to be issued: 17,201,886.
- Issue price: approximately AU$1.32 per CDI (5 CDIs = 1 share of Common Stock).
- Expected aggregate proceeds: approximately US$15 million (A$22.7 million).
- Placement agent fees: approximately US$0.8 million, payable in cash and CDIs.
- Closing date expected on or about August 19, 2025.
- The offering is being conducted under Regulation S for investors outside the United States.
AVITA Medical, Inc. announced the successful completion of an equity raise in Australia on August 12, 2025. The filing serves as a formal notification of the capital injection via a press release.
📋 Key Facts
- Successful completion of an equity raise in Australia.
- Announcement date: August 12, 2025.
- The information is provided under Item 8.01 (Other Events).
AVITA Medical, Inc. has entered into a Fifth Amendment to its Credit Agreement with affiliates of OrbiMed Advisors, LLC. The amendment provides temporary relief by lowering revenue covenants for the upcoming four quarters before returning to a $115 million threshold.
🚩 Red Flags
- Covenant relief indicates potential difficulty meeting existing financial benchmarks in the near term.
- Equity 'pay-to-play' element: Issuance of 400,000 shares to lenders as a condition for debt modification is dilutive and suggests lender leverage.
📋 Key Facts
- Fifth Amendment to Credit Agreement dated August 7, 2025.
- Revenue covenant adjusted downward: $73M (Q3 2025), $77M (Q4 2025), $90M (Q1 2026), and $103M (Q2 2026).
- Post-June 2026 revenue covenant remains at the original $115 million.
- Company to issue 400,000 shares of common stock to Lenders as a condition of the amendment.
- The share issuance will be registered via Form S-3.
AVITA Medical, Inc. announced the appointment of Dr. Michael Tarnoff to its Board of Directors, effective August 6, 2025. The appointment includes an annual cash retainer and a significant initial equity grant.
📋 Key Facts
- Dr. Michael Tarnoff appointed to the Board on August 6, 2025, to serve until the 2026 Annual Meeting of Stockholders.
- Dr. Tarnoff is deemed an independent director under Regulation S-K standards.
- Annual cash compensation for board services is set at $70,000.
- Initial equity grant valued at $210,000 (30% stock options, 70% restricted stock units) effective August 12, 2025.
- Dr. Tarnoff brings extensive medical leadership experience from Medtronic, Inc., Covidien plc, and Tufts Medical Center.
AVITA Medical, Inc. held its 2025 Annual Meeting of Stockholders on June 4, 2025, via remote communication. The meeting resulted in the election of seven directors and the ratification of Grant Thornton LLP as the independent auditor.
🚩 Red Flags
- Significant opposition to the Amended and Restated Omnibus Incentive Plan (Proposal 11), with approximately 3.65 million votes against vs. 6.87 million in favor, indicating notable shareholder dissent regarding dilution or compensation structure.
📋 Key Facts
- Stockholders approved an amendment to the 2020 Omnibus Incentive Plan, increasing available shares by 2,500,000 to a total of 6,750,000 shares.
- All seven directors named in the Proxy Statement were elected to the Board of Directors.
- Stockholders ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Approval was granted for equity awards (RSUs and options) to non-executive directors and CEO James Corbett.
- A non-binding advisory vote approved the compensation of named executive officers.
AVITA Medical, Inc. filed an 8-K to announce the amendment and restatement of its bylaws. The changes are intended to align company governance with recent updates in applicable laws regarding stockholder meetings and electronic notice procedures.
📋 Key Facts
- Effective May 15, 2025, the company's bylaws were amended and restated.
- Amendments relate to conduct of stockholder meetings and electronic notice requirements.
- The filing includes the full text of the amended bylaws as Exhibit 3.1.
AVITA Medical, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notification that a press release containing these results was issued on May 8, 2025.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: First quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
AVITA Medical entered into a new 10-year contract manufacturing agreement and an amendment to its exclusive distribution agreement with Stedical Scientific, Inc. The deal secures US manufacturing for PermeaDerm and increases AVITA's revenue share from 50% to 60%.
🚩 Red Flags
- The agreement includes performance-based milestone payments, which can create unpredictable expense/liability profiles if targets are met.
📋 Key Facts
- Entered into a Manufacturing Agreement with Stedical Scientific, Inc. on March 17, 2025.
- The agreement covers the manufacture of PermeaDerm® Biosynthetic Wound Matrix in the United States.
- Manufacturing is for US sales and for sale to Stedical Scientific for international distribution.
- The Manufacturing Agreement has a term of ten years.
- Amendment Two to the Distribution Agreement increases AVITA's revenue share from 50% to 60%.
- Stedical Scientific becomes eligible for milestone payments based on sales targets achieved by AVITA.
AVITA Medical has entered into a Fourth Amendment to its Credit Agreement with OrbiMed Advisors, LLC affiliates. The amendment provides relief by adjusting trailing 12-month revenue covenants downward through March 2026 and includes the issuance of warrants to lenders.
🚩 Red Flags
- Covenant Relief: The downward adjustment of revenue covenants suggests the company was at risk of breaching its original financial terms.
- Equity Dilution: Issuance of warrants to lenders at a nominal $0.01 exercise price represents significant potential dilution for existing shareholders.
📋 Key Facts
- Fourth Amendment signed on February 13, 2025, with OrbiMed Advisors, LLC affiliates.
- Revenue covenant for quarter ending March 31, 2025, is set at $73 million (down from a previous level).
- Revenue covenants scale up quarterly: $78M (June '25), $84M (Sept '25), $92M (Dec '25), and $103M (March '26).
- The long-term revenue covenant remains at $115 million for quarters following March 31, 2026.
- Company to issue warrants to Lenders for up to 145,180 shares of common stock.
- Warrants have an exercise price of $0.01 per share and a 10-year term.
AVITA Medical, Inc. issued a press release providing an update to its expected revenue for Q4 and full year 2024, while also issuing updated financial guidance for the fiscal year 2025.
🚩 Red Flags
- Revenue updates/guidance revisions often imply a deviation from previous analyst expectations or internal projections.
📋 Key Facts
- Report date: January 7, 2025
- The filing provides updates to expected Q4 and Full Year 2024 revenue.
- The company provided new financial guidance for the full year 2025.
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition).
AVITA Medical, Inc. announced its Q3 2024 financial results and simultaneously disclosed a significant amendment to its existing credit agreement with an affiliate of OrbiMed Advisors, LLC. The amendment involves the termination of $50 million in available debt tranches and the removal of a critical revenue covenant for Q4 2024.
🚩 Red Flags
- Termination of $50M in available debt capacity reduces liquidity/financial flexibility.
- Removal of the Q4 2024 revenue covenant suggests the company may have been at risk of breaching this specific metric, indicating potential performance struggles.
📋 Key Facts
- Company amended its credit agreement with an affiliate of OrbiMed Advisors, LLC on November 7, 2024.
- The amendment results in the termination of two additional debt tranches totaling $50.0 million.
- The Company will pay a consent fee to the Lender as part of the amendment.
- The trailing 12-month revenue covenant for Q4 2024 (previously set at $67.5 million) has been removed.
- Revenue covenants for all subsequent quarters remain in effect.
- Company issued a press release regarding Q3 financial results (Exhibit 99.1).
AVITA Medical, Inc. filed an 8-K to furnish its second quarter financial results for the period ended June 30, 2024. The filing serves as a formal announcement of the company's quarterly earnings via press release.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Second quarter ended June 30, 2024
- The filing includes Exhibit 99.1 containing the 'AVITA Medical Reports Second Quarter Financial Results' press release.
- Information is furnished under Item 2.02 and not filed for purposes of Section 18 of the Exchange Act.
AVITA Medical entered into an exclusive five-year development and distribution agreement with Regenity Biosciences for a collagen-based dermal matrix. The deal includes contingent milestone payments totaling up to $5.0 million and a revenue-sharing structure.
🚩 Red Flags
- Contingent liabilities: Up to $5 million in milestone payments tied to FDA clearance and clinical results.
📋 Key Facts
- Agreement date: July 31, 2024
- Term: Five years (with potential extension)
- Product: Collagen-based dermal matrix to be manufactured by Regenity Biosciences
- Milestone 1: $2.0 million payment upon FDA 510(k) clearance (expected Q4 2024)
- Milestone 2: $3.0 million contingent on positive clinical study results due by Jan 4, 2026
- Revenue sharing: 50% of average sales price for first two years; increasing to 60% in subsequent years
- Territories: U.S., EU (potential), Australia, and Japan
AVITA Medical, Inc. announced the immediate retirement of General Counsel, Compliance Officer, and Corporate Secretary Donna Shiroma, effective June 28, 2024. She is succeeded by Nicole Kelsey, a highly experienced legal professional with backgrounds at Medtronic and Amyris.
🚩 Red Flags
- Immediate departure of the General Counsel/Compliance Officer can sometimes signal internal friction, though the filing explicitly states there were no disagreements.
📋 Key Facts
- Donna Shiroma retired as General Counsel, Compliance Officer, and Corporate Secretary on June 28, 2024.
- Nicole Kelsey appointed as Chief Legal and Compliance Officer and Corporate Secretary, effective immediately.
- Ms. Shiroma will receive a lump sum salary payment of $453,000 and a prorated bonus of $113,250.
- The company provided 12 months of medical/dental/vision insurance premiums to Ms. Shiroma as part of her separation agreement.
- A one-month consulting agreement was entered into for transition services through July 31, 2024, at a cost of $40,000.
AVITA Medical, Inc. held its 2024 Annual Meeting of Stockholders on June 5, 2024. The meeting resulted in the election of seven directors and the ratification of Grant Thornton LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held virtually on June 5, 2024.
- All seven named directors were elected to the Board of Directors.
- Stockholders ratified the appointment of Grant Thornton LLP as independent auditors for the fiscal year ending December 31, 2024.
- Shareholders approved equity awards (RSUs and options) for non-executive directors.
- Shareholders approved a grant of 350,000 stock options to CEO James Corbett.
- A non-binding advisory vote on executive compensation was approved.
AVITA Medical, Inc. announced that it has received FDA approval for its premarket approval (PMA) supplement regarding the RECELL GO™ System.
📋 Key Facts
- FDA approved the PMA supplement for the RECELL GO™ System on May 30, 2024.
- The announcement was made via a press release attached as Exhibit 99.1.
AVITA Medical, Inc. filed an 8-K to furnish its first quarter financial results for the period ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Reporting Period: First Quarter ended March 31, 2024
- Filing Date: May 13, 2024
- Content: Results of operations and financial condition furnished in Exhibit 99.1
- Status: Information is 'furnished' rather than 'filed', meaning it lacks the same liability standard for certain securities laws.
AVITA Medical, Inc. issued an update regarding its expected revenue for the first quarter of 2024. The filing serves to furnish updated financial guidance via a press release.
📋 Key Facts
- The company issued a press release on April 10, 2024, updating its expected Q1 2024 revenue.
- The update is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
AVITA Medical, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023, and provided financial guidance for 2024.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Filing date: February 22, 2024.
- The filing includes a press release (Exhibit 99.1) containing financial results and 2024 guidance.
AVITA Medical's subsidiary, AVITA Americas, entered into an exclusive five-year distribution agreement with Stedical Scientific to commercialize PermeaDerm® Biosynthetic Wound Matrix in the U.S. The filing also includes preliminary 2023 financial results and 2024 guidance.
🚩 Red Flags
- Minimum purchase requirements: Failure to meet obligations for two consecutive years could lead to termination of the agreement.
- No right of return on products purchased from Stedical Scientific; AVITA holds title and risk of loss.
📋 Key Facts
- Exclusive multi-year distribution agreement for PermeaDerm® Biosynthetic Wound Matrix in the United States.
- Initial term is five years, with an option to automatically renew for another five years contingent on meeting minimums.
- AVITA Americas' gross margin from sales will be 50% of the average sales price.
- Agreement includes a 'Right of First Negotiation' regarding potential Change of Control transactions at Stedical Scientific.
- Provisions exist for AVITA to acquire manufacturing contracts if Stedical Scientific relocates facilities outside California.
- Company issued preliminary unaudited results for Q4 and full-year 2023 on January 10, 2024.